pirenzepine has been researched along with Intellectual Disability in 7 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
Excerpt | Relevance | Reference |
---|---|---|
" This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
" A numerical decrease in the dosage of concurrent conventional antipsychotic medications occurred over the course of the first 6 months of olanzapine therapy, and a statistically significant (p <." | 2.71 | Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. ( Barnhill, LJ; Davis, JM; Janowsky, DS, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Olson, DA | 1 |
Ingram, W | 1 |
Mann, JR | 1 |
Janowsky, DS | 1 |
Barnhill, LJ | 1 |
Davis, JM | 1 |
Glazer, WM | 1 |
Margolese, HC | 1 |
Chouinard, G | 1 |
Williams, H | 1 |
Clarke, R | 1 |
Bouras, N | 1 |
Martin, J | 1 |
Holt, G | 1 |
McDonough, M | 1 |
Hillery, J | 1 |
Kennedy, N | 1 |
Friedlander, R | 1 |
Lazar, S | 1 |
Klancnik, J | 1 |
1 review available for pirenzepine and Intellectual Disability
Article | Year |
---|---|
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
2 trials available for pirenzepine and Intellectual Disability
Article | Year |
---|---|
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disor | 2003 |
Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Inte | 2000 |
4 other studies available for pirenzepine and Intellectual Disability
Article | Year |
---|---|
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H | 2002 |
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Intellectual Disability; Male; Me | 1999 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M | 2001 |